My watch list  


Systematic (IUPAC) name
2-(2-(4-dibenzo[b,f][1,4]thiazepine- 11-yl-1-piperazinyl)ethoxy)ethanol
CAS number 111974-69-7
ATC code N05AH04
PubChem 5002
DrugBank APRD00675
Chemical data
Formula C21H25N3O2S 
Mol. mass 383.5099 g/mol
Pharmacokinetic data
Bioavailability 9%
Metabolism Hepatic
Half life 6 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.


Legal status


Routes Oral

Quetiapine (IPA: /kwəˈtɑɪəpiːn/, kwe-TYE-a-peen), marketed by AstraZeneca with the brand name Seroquel, belongs to a series of neuroleptics known as "atypical antipsychotics", which have, over the last two decades, become increasingly popular alternatives to "typical antipsychotics", such as haloperidol.



Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex. Quetiapine received its initial indication from the FDA for treatment of schizophrenia in 1997. In 2004, it received its second indication for the treatment of mania-associated bipolar disorder.[1] Quetiapine is controversially marketed to parents of moody and irritable teenagers in magazines such as Parade and TV Guide.[2][3] It is sometimes used off-label, often as an augmentation agent, to treat such conditions as obsessive-compulsive disorder, post-traumatic stress disorder, restless legs syndrome, autism, alcoholism, Tourette syndrome,[4] and has been used by physicians as a sedative for those with sleep disorders or anxiety disorders.

In 2005, quetiapine and other "atypical antipsychotics" were shown by the New England Journal of Medicine to be no more effective than perphenazine (Trilifon), a typical antipsychotic, for the treatment of schizophrenia. However, the subsequent CATIE trial, funded by AstraZeneca and other major pharmaceutical manufacturers,[5] contradicted the 2005 study in certain instances.

A 2005 British Medical Journal report showed that quetiapine was ineffective in reducing agitation among Alzheimer’s patients, whose consumption of the drug then constituted 29% of sales; in fact, quetiapine was found to make cognitive functioning worse in elderly patients with dementia.[6]

The National Institutes of Health recommends against the use of quetiapine and almost all other psychotropic medications (including all atypicals, most anti-depressants, and all benzodiazepines) by children or those under 18,[7] observing that teenagers taking quetiapine "may be more likely to think about harming or killing themselves or to plan or try to do so."[8]

AstraZeneca's patent for Seroquel expires September 2011, which will allow other companies to manufacture Seroquel as its generic equivalent quetiapine.


The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized.[citation needed] Serial PET scans evaluating the D2 receptor occupancy of quetiapine have demonstrated that quetiapine very rapidly disassociates from the D2 receptor.[citation needed] Theoretically, this allows for normal physiological surges of dopamine to elicit their normal effects in areas such as the nigrostriatal and tuberoinfundibular pathways, thus minimizing the risk of side effects such as pseudo-parkinsonism as well as elevations in prolactin.[citation needed]

Quetiapine also has an antagonistic effect on the histamine H1 receptor. This is thought to be responsible for the sedative effect of the drug.[9]


Quetiapine is available under the brand name Seroquel. It was originally available in 25 mg, 100 mg, 200 mg, and 300 mg tablets. Since then, 50 mg and 400 mg tablets were added to increase dosing flexibility.

Quetiapine Sustained Release (Seroquel XR)

AstraZeneca has submitted a New Drug Application for a sustained release version of quetiapine in the United States, Canada, and the European Union in the second half of 2006 for treatment of schizophrenia.[10][11] AstraZeneca will retain the exclusive right to market sustained release quetiapine until year 2017.

On May 18, 2007, AstraZeneca announced that U.S. Food and Drug Administration has approved Seroquel XR for acute treatment of schizophrenia.[12] During its 2007 Q2 earnings conference, AstraZeneca announced plans to launch Seroquel XR in the U.S. during August 2007.[13] However, Seroquel XR has only become available in U.S. pharmacies after FDA approved Seroquel XR for use as maintenance treatment for schizophrenia, in addition to acute treatment of the illness, on November 16, 2007.[14] The company has not provided a reason for the delay of Seroquel XR's launch.

Health Canada approved sale of Seroquel XR on September 27, 2007.[15]

Phase III trials are being conducted to prove quetiapine's efficacy in treating generalized anxiety disorder and major depressive disorder as of January 2007. The company expects to file New Drug Application for treating generalized anxiety disorder in the second half of 2007 and for major depressive disorder in 2008.[16]

Side effects

Quetiapine has many side effects, some of them common, a few of them serious and life-threatening.

The most common side effect of quetiapine is sedation. It is prescribed specifically (off-label) for this effect in patients with sleep disorders. Beginning users may feel extremely tired and 'out of it' for the first few days, sometimes longer. Quetiapine's newest indication, for bipolar depression, usually specifically calls for the entire dose to be taken before bedtime due to its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes, including insomnia and the treatment of anxiety disorders.

Common side effects include: constipation, headache, dry mouth, mild weight gain (or loss). Less common side effects (less than 1% of patients) include: abnormal liver tests, dizziness, upset stomach, substantial weight gain or weight loss, a stuffy nose, and increased paranoia.

There is a risk of development of tardive dyskinesia, an incurable neurological disorder, with any prolonged use of quetiapine and some other neuroleptic drugs. However, quetiapine is believed to cause tardive dyskinesia somewhat less often than typical antipsychotics based on the data sources which point to placebo-level incidence of extrapyramidal side effects.[17][18]

The rare, but life-threatening neuroleptic malignant syndrome may also result from quetiapine use.

Weight gain can be a problem for some patients using quetiapine, by causing the patient's appetite to persist even after meals. However, this effect may occur to a lesser degree compared to some other atypical antipsychotics such as olanzapine or clozapine. As with other atypical antipsychotics, there is evidence suggesting a link to the development of diabetes and blood sugar disorders, however this remains controversial due to disparities between the results of studies.

In the United States, two separate lawsuits—over claims that quetiapine use has led to diabetes—have been filed in federal court.[19]

Studies conducted on beagles have resulted in the formation of cataracts—while there are reports of cataracts occurring in humans, controlled studies including thousands of patients have not demonstrated a clear causal association between quetiapine therapy and this side effect. (Reference needed to April 2006 results of CATIE study.) However, the Seroquel website[20] still recommends users have eye examinations every six months.

As with some other antipsychotics, quetiapine may lower the seizure threshold, and should be taken with care in combination with drugs such as bupropion.

Addiction and abuse

Quetiapine is not currently classified as a controlled substance. Reports of quetiapine abuse have emerged in the medical literature, however, and while the drug is usually abused through the crushing and snorting of tablets (insufflation), there have also been reports of intravenous abuse and intravenous co-administration with cocaine.[21] A 2004 report recorded a 30% rate of inmate use in the Los Angeles County Jail, where the drug was obtained by inmates faking schizophrenic symptoms and resold under the street name "quell."[22] Also known as "Susie-Q," the drug may be more commonly abused in prisons due to its capacity to be regularly prescribed as a sedative and the unavailability in prison of more commonly-abused substances. It is unique among common "atypical antipsychotics"[citation needed] in showing a capacity for dependence, with inmates threatening legal action and suicide if not given prescriptions.[23]

Along with benzodiazepines, atypical antipsychotics have sometimes been used to "come down" off amphetamines. When used in this manner the slang term "downer" is often applied.


  1. ^ FAQ About Seroquel
  2. ^ "Debate Over Children and Psychiatric Drugs", New York Times, February 15, 2007.
  3. ^ Seroquel is an Antipsychotic.
  4. ^ Quetiapine treatment of children and adolescents with Tourette's disorder. Fall 2003, retrieved January 27, 2007.
  5. ^ New Schizophrenia Drugs No Better Than Cheaper Generics
  6. ^ Misogyny marketing.
  7. ^ Seroquel stories: understanding Seroquel, important safety information
  8. ^ National Institutes of Health, Medline guidelines for Quetiapine
  9. ^ Schizophrenia: From Circuits to Symptoms. Medscape Today. Retrieved on June 5, 2007.
  10. ^ AstraZeneca Submits an NDA For Sustained Release Formulation Seroquel XR™. For the treatment of schizophrenia. July 18, 2006, retrieved January 1, 2007
  11. ^ AstraZeneca Submits EU and Canadian Regulatory Filings for Sustained Release Formulation SEROQUEL XR™ for the Treatment of Schizophrenia. October 19, 2006, retrieved January 1, 2007
  12. ^ FDA Approves AstraZeneca’s Once-Daily SEROQUEL XR™ Extended-Release Tablets For The Treatment Of Schizophrenia. May 18, 2007, retrieved August 2, 2007
  13. ^ Second Quarter and Half Year Results 2007. July 26, 2007, retrieved August 2, 2007
  14. ^ Seroquel XR™ Receives Approval from FDA for Maintenance Treatment of Schizophrenia November 16, 2007. Retrieved December 3, 2007.
  15. ^ Notice of Compliance Information - Seroquel XR September 27, 2007, retrieved December 3, 2007
  16. ^ AstraZeneca—Pipeline Summary—New chemical entities and line extensions. Retrieved January 5, 2007
  17. ^ Quetiapine-related tardive dyskinesia..
  18. ^ Tardive dyskinesia with quetiapine..
  19. ^ Seroquel suit claims 'so much' is poured into marketing and away from research. The Madison St. Clair Record.
  20. ^
  21. ^ Intravenous Quetiapine-Cocaine Use ("Q-Ball")
  22. ^ Intranasal Quetiapine Abuse
  23. ^ Quetiapine addiction?
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Quetiapine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE